F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.89
    +0.04 (+1.04%)

    Market Cap: $296.80M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(18/29)
    Avg Surprise
    +48.08%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.13 - $-0.08
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.31-180.2%
    60d ago$-0.18-60.3%
    30d ago$-0.15-37.9%
    7d ago$-0.11+0.0%
    Current$-0.11
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.17 - $0.13
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.11---
    Jun 26
    Reported Jul 30
    		$-0.29$-0.21-36.48%Miss-2.4%
    Mar 26
    Reported Apr 27
    		$-0.25$-0.30+16.67%Beat+10.7%
    Dec 25
    Reported Feb 24
    		$-0.31$-0.31-1.47%Miss+0.0%
    Sep 25
    Reported Oct 29
    		$-0.31$-0.29-6.90%Miss+32.6%
    Jun 25
    Reported Jul 29
    		$-0.28$-0.29+3.45%Beat-132.2%
    Mar 25
    Reported May 1
    		$-0.28$-0.29+3.45%Beat+34.9%
    Dec 24
    Reported Feb 25
    		$-0.31$-0.29-7.53%Miss+22.5%
    Sep 24
    Reported Nov 13
    		$-0.46$-0.40-15.00%Miss-17.9%
    Jun 24
    Reported Jul 31
    		$0.87$0.06+1350.00%Beat+328.9%
    Mar 24
    Reported May 13
    		$-0.43$-0.44+2.27%Beat-4.9%
    Dec 23
    Reported Feb 27
    		$-0.40$-0.43+6.98%Beat+20.0%
    Sep 23
    Reported Nov 7
    		$-0.39$-0.44+11.36%Beat+22.0%
    Jun 23
    Reported Aug 3
    		$-0.38$-0.44+13.64%Beat+54.2%
    Mar 23
    Reported May 15
    		$-0.41$-0.46+10.87%Beat+35.9%
    Dec 22
    Reported Mar 9
    		$-0.50$-0.49-2.04%Miss+13.8%
    Sep 22
    Reported Nov 8
    		$-0.50$-0.61+18.03%Beat+12.3%
    Jun 22
    Reported Aug 11
    		$-0.83$-0.66-25.76%Miss-38.3%
    Mar 22
    Reported May 9
    		$-0.64$-0.63-1.59%Miss-18.5%
    Dec 21
    Reported Mar 3
    		$-0.58$-0.73+20.55%Beat+9.4%
    Sep 21
    Reported Nov 4
    		$-0.57$-0.65+12.31%Beat+18.6%
    Jun 21
    Reported Aug 10
    		$-0.60$-0.65+7.69%Beat+9.1%
    Mar 21
    Reported May 6
    		$-0.54$-0.66+18.18%Beat+33.3%
    Dec 20
    Reported Mar 4
    		$-0.64$-0.72+11.11%Beat+9.9%
    Sep 20
    Reported Nov 10
    		$-0.70$-0.64-9.38%Miss+27.8%
    Jun 20
    Reported Aug 11
    		$-0.66$-0.75+12.00%Beat+7.0%
    Mar 20
    Reported May 13
    		$-0.81$-0.75-8.00%Miss-161.3%
    Dec 19
    Reported Mar 5
    		$-0.71$-0.88+19.32%Beat-
    Sep 19
    Reported Nov 14
    		$-0.97$-0.72-34.72%Miss-
    Jun 19
    Reported Aug 26
    		$-0.71$-0.75+5.33%Beat-
    Mar 19
    Reported May 29
    		$-0.31$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.36EV/EBITDA-3.10x
    Price/FCF-4.49xFCF Yield-22.30%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-32.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio31.35xQuick Ratio31.35x
    Trading Statistics
    Beta2.58Avg Volume1.77M
    52-Week High$15.7452-Week Low$2.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.86
    SMA 20$3.81
    SMA 50$3.73
    SMA 200$7.43
    EMA 10$3.85
    EMA 20$3.82
    EMA 50$4.04
    EMA 200$6.00

    MACD

    Line: 0.02Signal: 0.01Hist: 0.01

    ADX

    ADX: 8.7+DI: 17.1-DI: 16.4

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down16.0
    PSAR$4.04

    Bollinger Bands

    Upper Band$3.95
    Lower Band$3.68
    %B Position690%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    55.5

    Momentum Oscillators

    Stoch %K76.4
    Stoch %D74.7
    Williams %R-15.4
    ROC (10d)1.3%
    Momentum0.05
    CCI (20d)74.7
    MFI (14d)73.2

    Volatility Measures

    ATR (14d)$0.13(3.3%)
    StdDev (20d)0.07
    Hist Vol24.5%(Moderate)

    Volume Flow

    VWAP$3.87
    OBV16.4M
    AD Line-667.2K
    CMF (20d)0.252

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.0x
    VWMA (20d)$3.83

    Pivot Points

    R3$3.98
    R2$3.92
    R1$3.89
    Pivot Point$3.83
    S1$3.80
    S2$3.74
    S3$3.71

    Advanced Oscillators

    TSI5.18
    Ultimate Osc62.6
    KST42.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$80.00M$0$871,000$759,000
    Cost of Revenue$0$0$-300,000$0$0$0$369,000$0$0$0$508,000$0
    Gross Profit$0$0$300,000$0$0$0$-369,000$0$80.00M$0$871,000$759,000
    Operating Expenses$29.31M$22.19M$22.69M$21.86M$19.82M$20.40M$19.43M$25.13M$27.51M$29.83M$28.86M$28.20M
    R&D$12.44M$14.08M$15.42M$14.30M$12.99M$13.40M$11.71M$14.64M$17.26M$19.77M$19.00M$18.24M
    SG&A$7.46M$8.10M$7.28M$7.56M$6.83M$7.00M$7.72M$8.42M$10.25M$10.06M$9.86M$9.96M
    Operating Income$-29,310,000$-22,186,000$-22,693,000$-21,858,000$-19,815,000$-20,403,000$-19,429,000$-25,126,000$52.49M$-29,834,000$-27,992,000$-27,440,000
    Interest Income$3.13M$3.29M$2.36M$2.26M$2.52M$2.75M$2.86M$3.43M$2.92M$2.96M$3.24M$3.42M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-26,179,000$-18,891,000$-20,334,000$-19,595,000$-17,296,000$-17,655,000$-16,568,000$-21,696,000$55.41M$-26,870,000$-24,756,000$-24,017,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-26,179,000$-18,891,000$-20,334,000$-19,595,000$-17,296,000$-17,655,000$-16,568,000$-21,696,000$55.41M$-26,870,000$-24,756,000$-24,017,000
    EBITDA$-29,905,000$-22,615,000$-22,729,000$-22,098,000$-20,556,000$-20,949,000$-20,005,000$-25,909,000$51.73M$-30,516,000$-28,812,000$-28,494,000
    EBIT$-29,310,000$-22,186,000$-22,693,000$-21,858,000$-19,815,000$-20,403,000$-19,429,000$-25,126,000$52.49M$-29,834,000$-27,992,000$-27,440,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FULC

    News

    Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

    Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's safety profile, leading to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is seeking investors who suffered losses or have information relevant to the investigation.

    The National Law Review•8/28/26•
    Bearish

    Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

    Kaplan Fox & Kilsheimer LLP has initiated an investigation into potential securities violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. This investigation stems from Fulcrum's announcement to discontinue its pociredir program for sickle cell disease due to FDA concerns regarding the malignancy risk associated with its PRC2 inhibitor. Investors who suffered losses are encouraged to contact Kaplan Fox.

    The National Law Review•8/26/26•
    Bearish

    Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

    Fulcrum Therapeutics (FULC) is undergoing an all-stock merger with Slate Medicines, transforming into a migraine-focused biotechnology company. The deal involves Slate holders owning 55.9%, PIPE investors 39.1%, and legacy Fulcrum holders 5% of the combined entity, with Fulcrum distributing an estimated $270 million cash dividend ($3.54/share). This transaction effectively offers Fulcrum shareholders a cash payout plus a small stake in Slate's migraine pipeline, which currently lacks human efficacy data.

    Yahoo Finance Singapore•8/25/26•
    Neutral

    Fulcrum Therapeutics stock plunges 51% after halting sickle cell drug due to FDA safety concerns

    Fulcrum Therapeutics' stock plummeted 51% after the company discontinued its sickle cell disease drug, pociredir, due to FDA safety concerns about a high rate of secondary blood cancers. This decision eliminated any viable regulatory path for the drug's development. Kaplan Fox & Kilsheimer LLP is now investigating potential securities violations, highlighting the significant regulatory risks in drug development for rare diseases.

    Pluang•8/24/26•
    Bearish

    Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC

    Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) and Slate Medicines, Inc. The law firm is examining whether the merger and its process are fair to Fulcrum shareholders, who are expected to own 5.0% of the combined company. Shareholders are encouraged to contact KSF for legal consultation regarding their rights.

    Business Wire•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About FULC

    Does FULC pay dividends?
    Fulcrum Therapeutics Inc (FULC) does not currently pay a regular dividend.
    What is FULC's market cap?
    Fulcrum Therapeutics Inc (FULC) has a market capitalization of $296.80M with a current stock price of $3.89.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In